Latest from the Blog

1. August 6, 2019

   A Missing Link to Glioblastoma Growth?

   

   An enzyme that serves as a link between oncogenes and the lipids that make-up cells’ membranes may be an important new drug target to treat glioblastoma and other tumors Glioblastoma, like all cancers, develops and progresses as cells begin to multiply and grow out of control, forming a tumor.  Mutations to a protein known as […]

   Read more | 

   Tags: brain cancer, brain tumor, Cancer, Defeat GBM, GBM, glioblastoma, glioma, high-grade glioma, precision medicine, Treatment
2. August 5, 2019

   NBTS Brain Tumor Clinical Trials Report – August 2019

   

   Brain tumor clinical trials open around the country all the time, and it can be hard for patients and care partners to keep track of new opportunities to consider participation in leading-edge clinical research. This report, generated by the National Brain Tumor Society, provides a summary of clinical trials that have started or begun recruitment […]

   Read more | 

   Tags: astrocytoma, biopharma, biotech, biotechnology, bipoharma, brain cancer, brain tumor, Cancer, chemotherapy, childhood cancer, Clinical trials, DIPG, FDA, GBM, glioblastoma, glioma, high-grade glioma, immunotherapy, low-grade glioma, Medulloblastoma, meningioma, NCI, neurosurgery, NIH, oligo, Oligodendroglioma, pediatric, pediatric brain tumor, pediatric cancer, pharmaceutical companies, precision medicine, Treatment
3. August 1, 2019

   Phase III Brain Tumor Clinical Trials Open for Patient Enrollment – July 2019 Update

   

   Below is a list of phase III clinical trials that are currently open for primary brain tumor patients in the United States. A phase III clinical trial is traditionally the last, pivotal step in the evaluation of a potential new medicine before it is approved for use by all patients with the indicated disease. Many of […]

   Read more | 

   Tags: astrocytoma, biopharma, biotech, biotechnology, brain cancer, brain tumor, Cancer, chemotherapy, childhood cancer, Clinical trials, DIPG, FDA, GBM, glioblastoma, glioblastoma multiforme, glioma, high-grade glioma, immunotherapy, low-grade glioma, Medulloblastoma, meningioma, NCI, neurosurgery, NIH, oligo, Oligodendroglioma, pediatric, pediatric brain tumor, pediatric cancer, pediatrics, pharmaceutical companies, precision medicine, Treatment